Portia S. Lombardo

Publications by Year

Research Areas

Cancer, Lipids, and Metabolism, Cancer, Hypoxia, and Metabolism, Peroxisome Proliferator-Activated Receptors, Lipid metabolism and disorders, Autophagy in Disease and Therapy

Most-Cited Works

• → Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models(2016)506 cited
• → Lipoprotein Lipase Links Dietary Fat to Solid Tumor Cell Proliferation(2011)284 cited
• → AMPK/ULK1-mediated phosphorylation of Parkin ACT domain mediates an early step in mitophagy(2021)152 cited
• → Abstract 1977: ACR-2316: A potentially first-in-class, potent, selective WEE1/PKMYT1 inhibitor rationally designed for superior single agent activity through synergistic disruption of cell cycle checkpoints(2024)1 cited
• Lipid metabolism in aggressive tumors(2010)
• → Abstract A097: Global pharmacodynamic effects uncovered with AP3 phosphoproteomic profiling of novel WEE1/PKMYT1 inhibitor ACR-2316 reveals the critical importance of PLK1 for ACR-2316’s superior preclinical activity and differentiated mechanism of action(2025)
• → Supplementary Figures 1-3, Table 1 from Lipoprotein Lipase Links Dietary Fat to Solid Tumor Cell Proliferation(2023)
• Phosphorylation of Parkin by the autophagy initiating kinase ULK1 regulates mitochondrial homeostasis(2017)
• → Abstract 357: Detailed mechanistic understanding of ACR-2316, a novel, clinical-stage WEE1/PKMYT1 inhibitor, rationally designed for superior single-agent activity through potent activation of CDK1, CDK2, and PLK1 using Acrivon’s machine learning-driven AP3 platform(2025)
• → Abstract 1256: A role for lipoprotein lipase in fatty acid acquisition by breast, prostate and liposarcoma tumors(2011)